2023-09-01 04:10:27
The National Vaccine Committee acknowledges the progress of the COVID-19 vaccine. By Thai people, the latest development of the HXP-GPOVAC vaccine, the organization is close to success! Waiting to see the results of the final phase of the test in the middle of September. If it’s good, ready to register with the FDA, it will be produced and used as early as the end of January – January. 67 As for the procurement, it is pending consideration of the Sub-Committee on Building Development and may propose using the NHSO budget.
on September 1 Mr. Anutin Charnvirakul, Deputy Prime Minister and Minister of Public Health (Sor Thor.) Interview following the meeting of the National Vaccine Committee Regarding the case of the Cabinet (Cabinet) approving the results of the loan expenditure screening committee (CDR) approving the Department of Disease Control to extend the deadline for the COVID-19 vaccine procurement program, that in addition to the cabinet acknowledging the results Such considerations meanwhile, the Department of Disease Control and the Ministry of Public Health There has been a previous parallel operation on the subject of negotiations with the manufacturer of the COVID vaccine. because now the situation with COVID is not the same as before and people to relax their concerns Rarely come for booster vaccination as they should. Therefore, there is a negotiation to reduce the booster needle. And request to change to ready-made antibodies or LAAB instead
“For people who are not vaccinated and infected, LAAB can still be treated, which is called both a vaccine and a cure. The price is higher than the vaccine. Therefore, I would like to leave that COVID-19 is still there, especially at risk groups should receive a stimulant needle and get an injection at the same time as the influenza vaccine. can be injected together, ”said Anutin.
COVID Vaccine HXP-GPOVAC Government Pharmaceutical Organization It’s almost finished. Use it at the end of the year.
side Dr. Nakorn Premsri, director of the National Vaccine Institute Said that for the COVID-19 vaccine in Thailand, it will be used as a booster vaccine. because although developed from the original species But still effective in preventing violence especially risk groups Elderly people with comorbidities when given a booster vaccine can reduce their severity. which today in Thailand there are still infected people who are still intubated especially the elderly with comorbidities vaccination in this group Immunity will occur less than normal people. Or the landscape falls faster, so the vaccine developed by Thailand will be used at this point. Along with the Thai registered vaccines, it can still be developed to support new strains. because in the future we do not know how to change Now Omicron, the next 6 months may change. Getting the first registration will be the basis for adapting to new species.
The reporter asked if the vaccine developed by Thai people would be owned by the Government Pharmaceutical Organization. Dr. Nakorn said yes, it is called the HXP-GPOVAC vaccine of the organization, waiting for the results of the third phase of testing, if the results are good, it will be registered with the Food and Drug Administration (FDA). .) This September Then it will be produced and available following registration. In total, it should be used by the end of this year. or maybe early January 2024
Dr. Nakorn added that There are still two types of vaccines developed by Thai people that have already been tested in humans: 1. ChulaCov19 mRNA vaccine by the Vaccine Research Center of Chulalongkorn University. Currently accepting volunteers for testing as a booster vaccine in Phase 1. The vaccine in the country is of good quality and suitable for human studies. Prepare volunteers for phase 2 studies for booster vaccination.
In the future, the COVID vaccine may be purchased through the NHSO.
The reporter asked if the organization had already produced the COVID vaccine. Regarding the source of the procurement budget, Dr. Nakorn said that it depends on the procurement method. If a specific method and still used in special conditions It’s bought directly from the budget. which the Subcommittee on Immunization is considering Will it be imported into the immunization program or not? Using budget from the National Health Security Office (NHSO) will be the next step. But any COVID-19 vaccine will be all in the process of consideration.
Details of the extension of the COVID vaccine project
Reporters reported that For the case of extending the termination of the COVID-19 vaccine procurement program For the population of Thailand, 60 million doses (AstraZeneca) in 2022 and the COVID-19 vaccine procurement program For the population of Thailand, 30 million doses (Pfizer) 2022 to end the project in March 2024 from the original end of the project in September 2023, because the case of AstraZeneca vaccine supply is pending a confirmation letter confirming the results of negotiations in Request to convert 19.07 million doses of undelivered vaccines to LAAB, Pfizer vaccination procurement program completed. However, the remainder of the vaccine is in the process of being managed in order to be consistent with the Pfizer (Maroon Cap) vaccine administration in the area.
1693543817
#promote #COVID19 #GPO #vaccine #successfully #produced #year #booster #procurement #budget #aims #offer #NHSO
